Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.
You may also be interested in...
HGS Follows Its Single-Cytokine BLISS In Lupus
Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.
HGS Follows Its Single-Cytokine BLISS In Lupus
Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.
Roche’s CellCept Gains “Black Box” Warning On Use During Pregnancy
FDA reinforces warning on increased risk of miscarriage, congenital deformities in light of postmarketing data from Roche, firm tells “The Pink Sheet” DAILY.